News
Eli Lilly sues four telehealth compounding GLP-1 companies
Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth companies were misleading consumers and illegally prescribing compounded versions of its glucagon-like peptide-1 agonist drugs Mounjaro and Zepbound.
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...
24/7 Wall St. on MSN7h
Eli Lilly Will Be the Next $1 Trillion StockEli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...
Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback